↓ Skip to main content

Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center

Overview of attention for article published in Revista da Associação Médica Brasileira, October 2016
Altmetric Badge

Citations

dimensions_citation
1 Dimensions

Readers on

mendeley
22 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center
Published in
Revista da Associação Médica Brasileira, October 2016
DOI 10.1590/1806-9282.62.07.641
Pubmed ID
Authors

Ramon Andrade Bezerra De-Mello, Carlos Pinho-Vaz, Rosa Branca, Fernando Campilho, Maria Rosales, Susana Roncon, António Campos-Júnior

Abstract

Allogeneic hematopoietic stem cell transplantation (ASCT) representes a potentially curative approach for patients with relapsed or refractory acute myeloid leukemia (AML). We report the outcome of relapsed/refractory AML patients treated with ASCT. A retrospective cohort from 1994 to 2013 that included 61 patients with diagnosis of relapsed/refractory AML. Outcomes of interest were transplant-related mortality (TRM), incidence of acute and chronic graft-versus-host disease (GVHD), relapse incidence, progression-free survival (PFS) and overall survival (OS). Statistical significance was set at p<0.05. The median age was 61 years (range 1 to 65). The cumulative incidence of 90 days, 1 year, and 3 years TRM were 60%, 26.7%, and 13.3%, respectively (p<0.001). The incidence of relapse was 21.7% at 1 year, 13% at 3 years, and 8.7% at 5 years. Median OS was estimated to be 8 months (95CI 3.266-12.734) and median PFS, 3 months (95CI 1.835-4.165). In our cohort, TRM in first years after ASCT remains considerable, but ASCT in this setting seems to be a good choice for AML patients with active disease. However, novel approaches are needed to reduce TRM and relapse in this set of patients.

Mendeley readers

The data shown below were compiled from readership statistics for 22 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 22 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 3 14%
Other 3 14%
Student > Master 3 14%
Student > Bachelor 3 14%
Researcher 2 9%
Other 5 23%
Unknown 3 14%
Readers by discipline Count As %
Medicine and Dentistry 8 36%
Biochemistry, Genetics and Molecular Biology 4 18%
Engineering 2 9%
Immunology and Microbiology 1 5%
Nursing and Health Professions 1 5%
Other 2 9%
Unknown 4 18%